PCIB: Extraordinary general meeting: Finansiering på plass
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 360 million
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS
WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA,
CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE
AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
PCI Biotech convenes an extraordinary general meeting to propose a fully
underwritten Rights Issue of NOK 360 million
Oslo, August 24, 2018 - PCI Biotech Holding ASA's ("PCI Biotech" or the
"Company") proposes to carry out a fully underwritten rights issue of NOK 360
million at a subscription price of NOK 30.00 per share, with pre-emptive
subscription rights for existing shareholders (the "Rights Issue"). The Board of
Directors has resolved to call for an extraordinary general meeting (the "EGM")
to be held on 14 September 2018 to resolve the Rights Issue. The notice of the
EGM will be distributed separately.
Per Walday, CEO of PCI Biotech, said: "We are very happy to announce this fully
underwritten rights issue that provides PCI Biotech with the funds needed to
perform the pivotal fimaChem study. The established underwriting syndicate shows
that we both have a supportive shareholder base and significant interest from
external investors, including a reputable international specialist investor. Our
focus is now to bring fimaChem to the market as quickly as possible, through
successful performance of the pivotal study."
Underwriting
The Rights Issue is fully underwritten, subject to customary terms and
conditions, by an underwriting syndicate established by ABG Sundal Collier and
Arctic Securities (the "Joint Bookrunners"). The Rights Issue is supported by
the Company's largest shareholders Fondsavanse, MP Pensjon, Myrlid and
Radiumhospitalets Forskningsstiftelse as significant underwriters. In addition,
the international specialist investor Nyenburgh as well as other institutional
investors have underwritten the remainder of the Rights Issue. The underwriters
will receive an underwriting fee equal to 3.50 per cent of their respective
underwriting obligations.
Stocken Invest AS, a company owned 100% by Lars Kåre Viksmoen, a member of the
Board of PCI Biotech, has entered into the underwriting agreement and has
underwritten NOK 1.0 million of the Rights Issue. Stocken Invest AS currently
owns 4,000 shares in PCI Biotech.
The Rights Issue
Completion of the Rights Issue is subject to shareholders' approval at the EGM
to be held on 14 September 2018 and that an EEA-prospectus for the Rights Issue
is approved by the Financial Supervisory Authority of Norway and published in
accordance with applicable laws.
Through the Rights Issue, the share capital of PCI Biotech will be increased by
NOK 36,000,000 through an issue of 12,000,000 new shares, each with a nominal
value of NOK 3.00. Shareholders in the Company as at close of trading on Oslo
Børs on 14 September 2018 (as evidenced in the VPS shareholder register on 18
September 2018, being the "Record Date"), who may lawfully participate in the
Rights Issue ("Eligible Shareholders"), will be granted subscription rights
giving a preferential right to subscribe for and be allocated new shares in the
Rights Issue, meaning that the share will trade exclusive of the right to
receive subscription rights from and including 17 September 2018 for trades
subject to ordinary T+2 settlement in the VPS. Each Eligible Shareholder will be
granted approximately 0.48 subscription rights for each existing share
registered as being held by such existing shareholders in the VPS as of the
Record Date. The number of subscription rights issued to each Eligible
Shareholder will be rounded down to the nearest whole subscription right. Each
subscription right will, subject to applicable securities laws, give the right
to subscribe for and be allocated one (1) new share in the Rights Issue. Over-
subscription by holders of subscription rights or subscription for shares
without subscription rights will be permitted. Further details of the terms of
the Rights Issue will be described in the prospectus to be released in
connection with commencement of the subscription period for the Rights Issue
(see indicative timeline below).
The subscription rights will be tradable and listed on Oslo Børs during the
subscription period for the Rights Issue. Any subscription rights not used or
sold during the subscription period will lapse and cease to carry any value.
The subscription price per new share in the Rights Issue is NOK 30.00 per share.
The subscription price corresponds to a discount of approximately 34 per cent to
the implied Theoretical Ex-Rights Price of NOK 45.61 based on PCI Biotech's
closing share price on 23 August 2018. Following completion of the Rights Issue,
the share capital of PCI Biotech will be NOK 110,984,670 consisting of
36,994,890 shares, each with a nominal value of NOK 3.00. The Rights Issue will
result in gross proceeds to PCI Biotech of NOK 360,000,000.
Below is an indicative time table for the Rights Issue:
14 September 2018: EGM to resolve the Rights Issue
14 September 2018: Last day of trading in PCI Biotech shares inclusive
subscription rights
17 September 2018: PCI Biotech shares trade excluding rights to participate in
the Rights Issue
18 September 2018: Record date for determining the right to receive subscription
rights, at which date the VPS shareholders register for trades with ordinary
settlement in VPS (T+2) will show shareholders of the Company as per the end of
trading on 14 September 2018.
On or about 19 September 2018: Publication of prospectus and first day of
subscription period for the Rights Issue
On or about 03 October 2018: Last day of subscription period for the Rights
Issue
On or about 08 October 2018: Allocation of new shares
On or about 10 October 2018: Payment for new shares
On or about 11 October 2018: Registration of share capital increase in the
Norwegian Register of Business Enterprises
ABG Sundal Collier and Arctic Securities are acting as Joint Bookrunners in
connection with the Rights Issue. Advokatfirmaet Selmer AS is acting as the
Company's legal advisor in connection with the Rights Issue.
Update on PCI Biotech's development programmes
The emerging data from the fimaChem Phase I dose-escalation study in inoperable
extrahepatic bile duct cancer continues to deliver positive early signs of
efficacy. Cohort IV included six patients at the dose level selected for pivotal
development and the results from this Cohort are now mature enough for
presentation. Although the results are based on small patient numbers, the
efficacy signs are very promising compared to the most relevant published
comparator data on treatment with standard of care. Attached is a summary table
with key Phase I data and references to the most relevant comparator data. The
pivotal study is intended to include up to two fimaChem treatments and the
safety of this regimen is studied in an extension to the Phase I study. By
August 2018, four patients have passed the safety window after the second
fimaChem treatment. The plan is to include an additional safety review by the
Independent Data Monitoring Committee (IDMC) after eight patients. The pivotal
study is expected to start early in 2019, with an interim analysis of
progression free survival and objective response rate for potential
accelerated/conditional approval available approx. 36 months after initiation.
For further information on timelines and study design, see attachment.
The advent of effective immunotherapeutics in several disease areas have
provided hope for a large number of patients, but therapeutic vaccination within
oncology has faced several setbacks in late stage development due to
insufficient efficacy. The fimaVacc technology has proven to be a strong inducer
of the cellular immune responses needed for therapeutic effect in animal models
and the initial clinical immune response results are promising. The Phase I
results indicate enhanced T-cell responses, with early responses and high
response rates at tolerable dose levels. There is a large commercial potential
in this technology, as there is a need for improved T-cell responses in both
therapeutic cancer vaccination and several infectious disease applications. The
near-term focus of this programme is to further characterise the immune
response.
The fimaNAc programme addresses a main challenge for the realisation of the vast
opportunity in nucleic acid therapeutics - effective intracellular delivery of
this class of large therapeutic molecules. Several of the key commercial players
in this therapeutic area continue to show interest in the fimaNAc technology and
the Company currently has six ongoing research collaborations. The most recent
collaborations, with IMV and Bavarian Nordic, were established over the last
couple of months. PCI Biotech intends to continue the collaborative strategy,
with the aim to convert research collaborations to commercial partnerships with
select companies.
Update on 2Q 2018 Financial Figures
The Company will report its full financial figures for 2Q 2018 on 30 August
2018.
Net results in 2Q 2018 amounted to NOK -7.1 million. At the end of 2Q 2018 the
Company's cash and cash equivalents amounted to NOK 28.4 million, a net change
of NOK -10.2 million relative to the figures reported for 1Q 2018.
https://newsweb.oslobors.no/message/45802
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS
WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA,
CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE
AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
PCI Biotech convenes an extraordinary general meeting to propose a fully
underwritten Rights Issue of NOK 360 million
Oslo, August 24, 2018 - PCI Biotech Holding ASA's ("PCI Biotech" or the
"Company") proposes to carry out a fully underwritten rights issue of NOK 360
million at a subscription price of NOK 30.00 per share, with pre-emptive
subscription rights for existing shareholders (the "Rights Issue"). The Board of
Directors has resolved to call for an extraordinary general meeting (the "EGM")
to be held on 14 September 2018 to resolve the Rights Issue. The notice of the
EGM will be distributed separately.
Per Walday, CEO of PCI Biotech, said: "We are very happy to announce this fully
underwritten rights issue that provides PCI Biotech with the funds needed to
perform the pivotal fimaChem study. The established underwriting syndicate shows
that we both have a supportive shareholder base and significant interest from
external investors, including a reputable international specialist investor. Our
focus is now to bring fimaChem to the market as quickly as possible, through
successful performance of the pivotal study."
Underwriting
The Rights Issue is fully underwritten, subject to customary terms and
conditions, by an underwriting syndicate established by ABG Sundal Collier and
Arctic Securities (the "Joint Bookrunners"). The Rights Issue is supported by
the Company's largest shareholders Fondsavanse, MP Pensjon, Myrlid and
Radiumhospitalets Forskningsstiftelse as significant underwriters. In addition,
the international specialist investor Nyenburgh as well as other institutional
investors have underwritten the remainder of the Rights Issue. The underwriters
will receive an underwriting fee equal to 3.50 per cent of their respective
underwriting obligations.
Stocken Invest AS, a company owned 100% by Lars Kåre Viksmoen, a member of the
Board of PCI Biotech, has entered into the underwriting agreement and has
underwritten NOK 1.0 million of the Rights Issue. Stocken Invest AS currently
owns 4,000 shares in PCI Biotech.
The Rights Issue
Completion of the Rights Issue is subject to shareholders' approval at the EGM
to be held on 14 September 2018 and that an EEA-prospectus for the Rights Issue
is approved by the Financial Supervisory Authority of Norway and published in
accordance with applicable laws.
Through the Rights Issue, the share capital of PCI Biotech will be increased by
NOK 36,000,000 through an issue of 12,000,000 new shares, each with a nominal
value of NOK 3.00. Shareholders in the Company as at close of trading on Oslo
Børs on 14 September 2018 (as evidenced in the VPS shareholder register on 18
September 2018, being the "Record Date"), who may lawfully participate in the
Rights Issue ("Eligible Shareholders"), will be granted subscription rights
giving a preferential right to subscribe for and be allocated new shares in the
Rights Issue, meaning that the share will trade exclusive of the right to
receive subscription rights from and including 17 September 2018 for trades
subject to ordinary T+2 settlement in the VPS. Each Eligible Shareholder will be
granted approximately 0.48 subscription rights for each existing share
registered as being held by such existing shareholders in the VPS as of the
Record Date. The number of subscription rights issued to each Eligible
Shareholder will be rounded down to the nearest whole subscription right. Each
subscription right will, subject to applicable securities laws, give the right
to subscribe for and be allocated one (1) new share in the Rights Issue. Over-
subscription by holders of subscription rights or subscription for shares
without subscription rights will be permitted. Further details of the terms of
the Rights Issue will be described in the prospectus to be released in
connection with commencement of the subscription period for the Rights Issue
(see indicative timeline below).
The subscription rights will be tradable and listed on Oslo Børs during the
subscription period for the Rights Issue. Any subscription rights not used or
sold during the subscription period will lapse and cease to carry any value.
The subscription price per new share in the Rights Issue is NOK 30.00 per share.
The subscription price corresponds to a discount of approximately 34 per cent to
the implied Theoretical Ex-Rights Price of NOK 45.61 based on PCI Biotech's
closing share price on 23 August 2018. Following completion of the Rights Issue,
the share capital of PCI Biotech will be NOK 110,984,670 consisting of
36,994,890 shares, each with a nominal value of NOK 3.00. The Rights Issue will
result in gross proceeds to PCI Biotech of NOK 360,000,000.
Below is an indicative time table for the Rights Issue:
14 September 2018: EGM to resolve the Rights Issue
14 September 2018: Last day of trading in PCI Biotech shares inclusive
subscription rights
17 September 2018: PCI Biotech shares trade excluding rights to participate in
the Rights Issue
18 September 2018: Record date for determining the right to receive subscription
rights, at which date the VPS shareholders register for trades with ordinary
settlement in VPS (T+2) will show shareholders of the Company as per the end of
trading on 14 September 2018.
On or about 19 September 2018: Publication of prospectus and first day of
subscription period for the Rights Issue
On or about 03 October 2018: Last day of subscription period for the Rights
Issue
On or about 08 October 2018: Allocation of new shares
On or about 10 October 2018: Payment for new shares
On or about 11 October 2018: Registration of share capital increase in the
Norwegian Register of Business Enterprises
ABG Sundal Collier and Arctic Securities are acting as Joint Bookrunners in
connection with the Rights Issue. Advokatfirmaet Selmer AS is acting as the
Company's legal advisor in connection with the Rights Issue.
Update on PCI Biotech's development programmes
The emerging data from the fimaChem Phase I dose-escalation study in inoperable
extrahepatic bile duct cancer continues to deliver positive early signs of
efficacy. Cohort IV included six patients at the dose level selected for pivotal
development and the results from this Cohort are now mature enough for
presentation. Although the results are based on small patient numbers, the
efficacy signs are very promising compared to the most relevant published
comparator data on treatment with standard of care. Attached is a summary table
with key Phase I data and references to the most relevant comparator data. The
pivotal study is intended to include up to two fimaChem treatments and the
safety of this regimen is studied in an extension to the Phase I study. By
August 2018, four patients have passed the safety window after the second
fimaChem treatment. The plan is to include an additional safety review by the
Independent Data Monitoring Committee (IDMC) after eight patients. The pivotal
study is expected to start early in 2019, with an interim analysis of
progression free survival and objective response rate for potential
accelerated/conditional approval available approx. 36 months after initiation.
For further information on timelines and study design, see attachment.
The advent of effective immunotherapeutics in several disease areas have
provided hope for a large number of patients, but therapeutic vaccination within
oncology has faced several setbacks in late stage development due to
insufficient efficacy. The fimaVacc technology has proven to be a strong inducer
of the cellular immune responses needed for therapeutic effect in animal models
and the initial clinical immune response results are promising. The Phase I
results indicate enhanced T-cell responses, with early responses and high
response rates at tolerable dose levels. There is a large commercial potential
in this technology, as there is a need for improved T-cell responses in both
therapeutic cancer vaccination and several infectious disease applications. The
near-term focus of this programme is to further characterise the immune
response.
The fimaNAc programme addresses a main challenge for the realisation of the vast
opportunity in nucleic acid therapeutics - effective intracellular delivery of
this class of large therapeutic molecules. Several of the key commercial players
in this therapeutic area continue to show interest in the fimaNAc technology and
the Company currently has six ongoing research collaborations. The most recent
collaborations, with IMV and Bavarian Nordic, were established over the last
couple of months. PCI Biotech intends to continue the collaborative strategy,
with the aim to convert research collaborations to commercial partnerships with
select companies.
Update on 2Q 2018 Financial Figures
The Company will report its full financial figures for 2Q 2018 on 30 August
2018.
Net results in 2Q 2018 amounted to NOK -7.1 million. At the end of 2Q 2018 the
Company's cash and cash equivalents amounted to NOK 28.4 million, a net change
of NOK -10.2 million relative to the figures reported for 1Q 2018.
https://newsweb.oslobors.no/message/45802
Redigert 21.01.2021 kl 08:49
Du må logge inn for å svare
Scoopfinder
24.08.2018 kl 07:52
10818
Altså er safety og effekt av dobbel behandling som vi kunne forvente.
Spenn setebeltet ?
Spenn setebeltet ?
Redigert 24.08.2018 kl 07:52
Du må logge inn for å svare
Kibote
24.08.2018 kl 07:55
10771
Blir spennende å se om kursen holder seg like godt denne gangen som i fjor. Hvis kursen først går under 30,- blir jo tegningsrettighetene verdiløse, men forhåpentligvis holder kursen deg godt over og da vil småaksjonærene ønske å bli sittende for å få tegnet aksjer til 30,-.
Krysser fingrene for at dette går like bra som forrige gang!
Krysser fingrene for at dette går like bra som forrige gang!
Rola
24.08.2018 kl 08:00
10952
Da er teknologien bekreftet. Fulltegnet. Spesial investor på plass. Pivotal fase start tidlig 2019.
Imponerende håndverk.
Teoretisk emisjon kurs cirka 45kr. Veldig bra.
Selskapet har nå bekreftet pivotal fase klar og fullfinansiert. Endelig spesial investor.
Er veldig imponert over ansatte, ledelse, advisory board og styret som nå har fått denne teknologien opp og fram. Fortsatt AA mål.
Congrats!
Imponerende håndverk.
Teoretisk emisjon kurs cirka 45kr. Veldig bra.
Selskapet har nå bekreftet pivotal fase klar og fullfinansiert. Endelig spesial investor.
Er veldig imponert over ansatte, ledelse, advisory board og styret som nå har fått denne teknologien opp og fram. Fortsatt AA mål.
Congrats!
Rola
24.08.2018 kl 08:11
10852
Kursen kan for alt jeg vet stige 50% i dag på bekreftet pivotal fase gjennomføring, spesial investor og garantert emi. Flere likte slik finansiering sist. Uansett nå er pivotal fase i mål. Spennende å se om det også blir Asia sites.
gepard1
24.08.2018 kl 08:16
10790
Safety paa plass. Og de hadde ikke gaatt videre med dobbel behandling, hvis ikke den dobble behandlingen gir bedre resultater.. Slik at det maa og anses og vaere i box. Og ingen foruten PCIB vet bedre om dette fungerer eller ikke enn Radiumhospitalet forskingsstiftelse, som ikke ville stillt seg bak emisjonen hvis de ikke var sikre paa at dette gaar i maal.
The
pivotal study is intended to include up to two fimaChem treatments and the
safety of this regimen is studied in an extension to the Phase I study. By
August 2018, four patients have passed the safety window after the second
fimaChem treatment. The plan is to include an additional safety review by the
Independent Data Monitoring Committee (IDMC) after eight patients. The pivotal
study is expected to start early in 2019, with an interim analysis of
progression free survival and objective response rate for potential
accelerated/conditional approval available approx. 36 months after initiation.
The
pivotal study is intended to include up to two fimaChem treatments and the
safety of this regimen is studied in an extension to the Phase I study. By
August 2018, four patients have passed the safety window after the second
fimaChem treatment. The plan is to include an additional safety review by the
Independent Data Monitoring Committee (IDMC) after eight patients. The pivotal
study is expected to start early in 2019, with an interim analysis of
progression free survival and objective response rate for potential
accelerated/conditional approval available approx. 36 months after initiation.
Redigert 24.08.2018 kl 08:25
Du må logge inn for å svare
Lothian
24.08.2018 kl 08:16
10759
Ingen Asia sites i presentasjonen, men 40 sites i USA og Europa.
Blir overrasket hvis markedet ikkje tar dagens nyheter vel imot...
Lothian.
Blir overrasket hvis markedet ikkje tar dagens nyheter vel imot...
Lothian.
oxion
24.08.2018 kl 08:23
10681
Håper markedet skjønner dette, for da bør vi fly forbi 60kr i dag.
Gratulerer Alle Sammen !!!!!
Gratulerer Alle Sammen !!!!!
bateman
24.08.2018 kl 08:26
10603
Stilig å se at styremedlem klinker til og handler aksjer for 1 million kroner!
''Styremedlem Lars Kåre Viksmoen i PCI Biotech har garantert for en million kroner i emisjonen gjennom Stocken Invest. Selskapet hans har 4.000 aksjer i selskapet i dag.''
Underwriting
The Rights Issue is fully underwritten, subject to customary terms and conditions, by an underwriting syndicate established by ABG Sundal Collier and Arctic Securities (the "Joint Bookrunners"). The Rights Issue is supported by the Company’s largest shareholders Fondsavanse, MP Pensjon, Myrlid and Radiumhospitalets Forskningsstiftelse as significant underwriters. In addition, the international specialist investor Nyenburgh as well as other institutional investors have underwritten the remainder of the Rights Issue. The underwriters will receive an underwriting fee equal to 3.50 per cent of their respective underwriting obligations.
Stocken Invest AS, a company owned 100% by Lars Kåre Viksmoen, a member of the Board of PCI Biotech, has entered into the underwriting agreement and has underwritten NOK 1.0 million of the Rights Issue. Stocken Invest AS currently owns 4,000 shares in PCI Biotech.
''Styremedlem Lars Kåre Viksmoen i PCI Biotech har garantert for en million kroner i emisjonen gjennom Stocken Invest. Selskapet hans har 4.000 aksjer i selskapet i dag.''
Underwriting
The Rights Issue is fully underwritten, subject to customary terms and conditions, by an underwriting syndicate established by ABG Sundal Collier and Arctic Securities (the "Joint Bookrunners"). The Rights Issue is supported by the Company’s largest shareholders Fondsavanse, MP Pensjon, Myrlid and Radiumhospitalets Forskningsstiftelse as significant underwriters. In addition, the international specialist investor Nyenburgh as well as other institutional investors have underwritten the remainder of the Rights Issue. The underwriters will receive an underwriting fee equal to 3.50 per cent of their respective underwriting obligations.
Stocken Invest AS, a company owned 100% by Lars Kåre Viksmoen, a member of the Board of PCI Biotech, has entered into the underwriting agreement and has underwritten NOK 1.0 million of the Rights Issue. Stocken Invest AS currently owns 4,000 shares in PCI Biotech.
Redigert 24.08.2018 kl 08:30
Du må logge inn for å svare
Bonusfrelst
24.08.2018 kl 08:29
10538
Andor skrev Meget bra at vi også får være med i emisjonen.,
Glimrende. Jeg blir med som forrige gang. Har nok til fulltegning. Reaksjonen blir nok som forrige emisjon. Når markedet skjønner at billige aksjer ikke blir gitt bort vil kursen mer enn dobles. Her må man fokusere på det kliniske som er utsøkt. Safety dobbel behandling ok og det er en grunn til at dette er inkludert i pf2: Bedre resultater
bateman
24.08.2018 kl 08:31
10499
Ikke feil å være fullfinansiert til 2022, nå når det mest sannsynlig foreligger et børskrakk i løpet av 0-12 måneder.
trigger1
24.08.2018 kl 08:33
10450
Same procedure as last time! Og det ble jo bra. Har hele tiden ønsket at de kjørte en emisjon i stedet for å hente inn en partner nå. Dette vil gi et helt annet verdigrunnlag (forutsatt selvfølgelig at pivotalstudien går bra). Så kan man spørre seg om hvorfor de måtte såpass langt ned i kurs for å få satt garantikonsortiet. Svaret er vel så enkelt som at makta rår, og det er kjappe 3,5% for garantistene. Men for oss andre som har tenkt å fulltegne eller overtegne er dette helt ok.
Durable
24.08.2018 kl 08:36
10716
Dette kan gi akskjekursen en kjempe-boost!
Forrige gang gikk den jo fra 5kr til over 20kr på tilsvarende opplegg.
Og nå er jo nyheter om safety og oppstart for pivotal fase to presentert i tillegg.
Det bør bli et rotterace om å karre til seg flest mulig aksjer og tegningsretter de neste ukene, og en slik kraftig økning på kjøpersiden bør jo resultere i stigning av aksjekursen.
Dersom den, mot formodning, skulle få en midlertidig nedgang kortsiktig er det bare å takke og bukke og ta imot. Mest sannsynlig vil det da være fordi de store finans-hyenene forsøker å utnytte at mannen i gata ikke forstår opplegget med tegningsretter og blir usikker.
Forrige gang gikk den jo fra 5kr til over 20kr på tilsvarende opplegg.
Og nå er jo nyheter om safety og oppstart for pivotal fase to presentert i tillegg.
Det bør bli et rotterace om å karre til seg flest mulig aksjer og tegningsretter de neste ukene, og en slik kraftig økning på kjøpersiden bør jo resultere i stigning av aksjekursen.
Dersom den, mot formodning, skulle få en midlertidig nedgang kortsiktig er det bare å takke og bukke og ta imot. Mest sannsynlig vil det da være fordi de store finans-hyenene forsøker å utnytte at mannen i gata ikke forstår opplegget med tegningsretter og blir usikker.
columna
24.08.2018 kl 08:41
10601
Kajsen
24.08.2018 kl 08:58
10432
Herregud, tror dere på det dere skriver. En emisjon med en rabatt på 45%. Aksjen skal selvfølgelig kraftig ned.
Kajsen
24.08.2018 kl 08:58
10419
Herregud, tror dere på det dere skriver. En emisjon med en rabatt på 45%. Aksjen skal selvfølgelig kraftig ned.
Ser man det ja, Dere skulle hørt på gamle hartvigsen 1. Synd for alle som har kjøpt noe over 30.- ;(
Rola
24.08.2018 kl 09:06
10281
Klart en tror på det en skriver. Det gikk ekstremt bra ved tilsvarende finansieringsløsning sist. Nesten 400% oppgang.
Nå er mye av usikkerheten borte. Klart det er verdt mye.
Nå er mye av usikkerheten borte. Klart det er verdt mye.
Bonusfrelst
24.08.2018 kl 09:06
10262
Hadde jeg hørt på deg hadde jeg ikke kjøpt aksjer til 7 kr for ca 2 år siden!
Kappa3278
24.08.2018 kl 09:07
10242
Aksjen rævkjøres, blir en stygg dag, tror vik kan se tre tallet i løpet av dagen
Snøffelen
24.08.2018 kl 09:07
10229
Rola sier:
"Da er teknologien bekreftet. Fulltegnet. Spesial investor på plass. Pivotal fase start tidlig 2019.
Imponerende håndverk.
Teoretisk emisjon kurs cirka 45kr. Veldig bra.
Selskapet har nå bekreftet pivotal fase klar og fullfinansiert. Endelig spesial investor.
Er veldig imponert over ansatte, ledelse, advisory board og styret som nå har fått denne teknologien opp og fram. Fortsatt AA mål.
Congrats! "
Synes det er et veldig riktig utgangspunkt.
Så får man justere for at ingen økonomiske bekymringer henger over selskapet, vi er opplagt klare for PF2 med dobbel behandling og safety fra extension-study er på plass.
Jeg ser ingen grunn til at vi nå ikke snarlig bør ha samme verdi som NANO, minst, og da snakker vi 82 kroner aksjen, fully diluted.
"Da er teknologien bekreftet. Fulltegnet. Spesial investor på plass. Pivotal fase start tidlig 2019.
Imponerende håndverk.
Teoretisk emisjon kurs cirka 45kr. Veldig bra.
Selskapet har nå bekreftet pivotal fase klar og fullfinansiert. Endelig spesial investor.
Er veldig imponert over ansatte, ledelse, advisory board og styret som nå har fått denne teknologien opp og fram. Fortsatt AA mål.
Congrats! "
Synes det er et veldig riktig utgangspunkt.
Så får man justere for at ingen økonomiske bekymringer henger over selskapet, vi er opplagt klare for PF2 med dobbel behandling og safety fra extension-study er på plass.
Jeg ser ingen grunn til at vi nå ikke snarlig bør ha samme verdi som NANO, minst, og da snakker vi 82 kroner aksjen, fully diluted.
Rola
24.08.2018 kl 09:09
10197
Hver aksje gir t rett. Med andre ord emi kurs på 45kr. 30 kr emi kurs pluss ca 15kr i verdi t rett er lik 45. Ender kursen i 60kr er t rett verdt ca 30kr, mao 90 kr teoretisk emi kurs.
Bonus
Vel, hvis du ikke aner at det finnes andre aksjer så lever du bra med din investering ;)
Vel, hvis du ikke aner at det finnes andre aksjer så lever du bra med din investering ;)
olemt
24.08.2018 kl 09:15
10079
Jeg doblet beholdning i åpningsauksjonen og ser frem til å delta i emisjonen.
riskypick
24.08.2018 kl 09:16
10064
PCIB gjengen altså. De jubler uansett. Man var jo fiendtlig innstilt til at noen skulle lure seg inn her til kurser under 100. Nå kom virkeligheten. Og attpåtil har man nesten doblet fee til garantister fra sist. Jøsses sier jeg. 3,5% haha. Her forsvinner mye til meglerhus og garantister. Jeg har vært positiv til dette opplegget PCIB kjører.
oxion
24.08.2018 kl 09:22
9990
totalt forvirring. storkapitalen jubler!!!
jaja underets tid er ikke forbi .
Dette er total misforståelse...
jaja underets tid er ikke forbi .
Dette er total misforståelse...
Jeg tror nesten jeg må grave frem 'bloggen' min . Ikke av skadefryd , men til skrekk og advarsel for fremtidige generasjoner ;)
Serboss
24.08.2018 kl 09:25
9925
Last day including right: 14 September 2018
Ex-date: 17 September 2018
Record Date: 18 September 2018
----------------------------------------------
Man blir tildelt T-retter per antall aksjer man har den 17 sept...
men jeg fan ikke ut hvor mange t-retter man faar tildelt/per aksje ?
Noen som vet ?
Ex-date: 17 September 2018
Record Date: 18 September 2018
----------------------------------------------
Man blir tildelt T-retter per antall aksjer man har den 17 sept...
men jeg fan ikke ut hvor mange t-retter man faar tildelt/per aksje ?
Noen som vet ?
Redigert 24.08.2018 kl 09:27
Du må logge inn for å svare
karlman
24.08.2018 kl 09:30
9837
@Snøffelen:
Tror ikke mange har fått med seg hva denne melding innebærer. Tror ikke heller mange har fått med seg at de får 0,48 rett per aksje.
Tror ikke mange har fått med seg hva denne melding innebærer. Tror ikke heller mange har fått med seg at de får 0,48 rett per aksje.
bateman
24.08.2018 kl 09:37
9753
Dagens handelsmønster minner mer om kaos og panikk. Dette kan utnyttes for dem med penger og hodet.
Deepmind
24.08.2018 kl 09:43
9671
Er nok en del som må selge fordi de ikke kan finansiere nye aksjer i en emisjon, da blir det fort litt panikk. Vanskelig å si hvor dette bærer, men jeg har tatt en sjanse og kjøpt litt. Edit: Med hvor det bærer tenker jeg på kursen på kort sikt.
Redigert 24.08.2018 kl 09:44
Du må logge inn for å svare
Durable
24.08.2018 kl 09:44
9653
Helt utrolig. :-) Her er det bare å holde hodet kaldt, sitte roooolig i båten og smile. :-)